TY - JOUR
T1 - Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations
AU - Korde, Larissa A.
AU - Zujewski, Jo Anne
AU - Kamin, Leah
AU - Giordano, Sharon
AU - Domchek, Susan
AU - Anderson, William F.
AU - Bartlett, John M. S.
AU - Gelmon, Karen
AU - Nahleh, Zeina
AU - Bergh, Jonas
AU - Cutuli, Bruno
AU - Pruneri, Giancarlo
AU - McCaskill-Stevens, Worta
AU - Gralow, Julie
AU - Hortobagyi, Gabriel
AU - Cardoso, Fatima
PY - 2010/4/20
Y1 - 2010/4/20
N2 - Male breast cancer is a rare disease, accounting for less than 1% of all breast cancer diagnoses worldwide. Most data on male breast cancer comes from small single-institution studies, and because of the paucity of data, the optimal treatment for male breast cancer is not known. This article summarizes a multidisciplinary international meeting on male breast cancer, sponsored by the National Institutes of Health Office of Rare Diseases and the National Cancer Institute Divisions of Cancer Epidemiology and Genetics and Cancer Treatment and Diagnosis. The meeting included representatives from the fields of epidemiology, genetics, pathology and molecular biology, health services research, and clinical oncology and the advocacy community, with a comprehensive review of the data. Presentations focused on highlighting differences and similarities between breast cancer in males and females. To enhance our understanding of male breast cancer, international consortia are necessary. Therefore, the Breast International Group and North American Breast Cancer Group have joined efforts to develop an International Male Breast Cancer Program and to pool epidemiologic data, clinical information, and tumor specimens. This international collaboration will also facilitate the future planning of clinical trials that can address essential questions in the treatment of male breast cancer. J Clin Oncol 28: 2114- 2122. (C) 2010 by American Society of Clinical Oncology
AB - Male breast cancer is a rare disease, accounting for less than 1% of all breast cancer diagnoses worldwide. Most data on male breast cancer comes from small single-institution studies, and because of the paucity of data, the optimal treatment for male breast cancer is not known. This article summarizes a multidisciplinary international meeting on male breast cancer, sponsored by the National Institutes of Health Office of Rare Diseases and the National Cancer Institute Divisions of Cancer Epidemiology and Genetics and Cancer Treatment and Diagnosis. The meeting included representatives from the fields of epidemiology, genetics, pathology and molecular biology, health services research, and clinical oncology and the advocacy community, with a comprehensive review of the data. Presentations focused on highlighting differences and similarities between breast cancer in males and females. To enhance our understanding of male breast cancer, international consortia are necessary. Therefore, the Breast International Group and North American Breast Cancer Group have joined efforts to develop an International Male Breast Cancer Program and to pool epidemiologic data, clinical information, and tumor specimens. This international collaboration will also facilitate the future planning of clinical trials that can address essential questions in the treatment of male breast cancer. J Clin Oncol 28: 2114- 2122. (C) 2010 by American Society of Clinical Oncology
U2 - 10.1200/JCO.2009.25.5729
DO - 10.1200/JCO.2009.25.5729
M3 - Article
SN - 0732-183X
VL - 28
SP - 2114
EP - 2122
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 12
ER -